Want to see MGTX full AI Analyst Report?
MGTX Stock Chart & Stats
$10.12
-$0.03(-0.47%)
At close: 4:00 PM EST
$10.12
-$0.03(-0.47%)
Day’s Range― - ―
52-Week Range$6.62 - $13.94
Previous CloseN/A
Volume124.17K
Average Volume (3M)809.27K
Market Cap
$1.29B
Enterprise Value$980.06M
Total Cash (Recent Filing)$71.54M
Total Debt (Recent Filing)$87.53M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 06, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.48
Shares Outstanding92,609,510
10 Day Avg. Volume821,340
30 Day Avg. Volume809,272
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-110.38
Price to Sales (P/S)7.86
P/FCF Ratio-12.74
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue12.29
Enterprise Value/Gross Profit13.41
Enterprise Value/Ebitda-10.24
Forecast
1Y Price Target
$27.50Price Target Upside171.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.66
Revenue Forecast (FY)$49.29M
Bulls Say, Bears Say
Bulls Say
High Gross MarginA ~94% gross margin indicates MeiraGTx captures high value on its revenue base, a durable structural advantage for gene therapies. If the company scales product sales, such margins can convert revenue growth into lasting operating leverage and support long-term profitability once fixed R&D and SG&A are absorbed.
Improving Operating Cash GenerationOperating cash flow turning positive (~$8M TTM) signals improving cash generation from core activities. This trend reduces near-term liquidity pressure, supports ongoing development spending without immediate operational draws on financing, and is a constructive step toward sustainable free cash flow.
Stronger Program Control And FundingThe April equity raise, strategic Hologen collaboration and reacquisition of bota-vec consolidate program ownership and provide multi-year funding runway. Together they bolster development and commercialization optionality, de-risk manufacturing via partnership and give MeiraGTx control to capture long-term product economics if approvals succeed.
Bears Say
Large Ongoing Net LossesSustained net losses (~$121M TTM) versus modest revenue mean MeiraGTx must materially scale sales or cut costs to reach break-even. Persistent losses limit reinvestment without external capital, increase dilution risk from future financings, and make multi-quarter profit recovery dependent on successful clinical-to-commercial transitions.
Negative Shareholders' EquityNegative equity (~-$58M) reflects cumulative losses and constrains financial flexibility. It can limit access to non-dilutive financing, raise counterparty concerns, and force reliance on equity raises or partnerships for capital needs—a structural corporate governance and funding headwind over the medium term.
Free Cash Flow Deficit And VolatilityAlthough operating cash turned positive, FCF remains slightly negative and has deteriorated materially, indicating heavy investing or working-capital demands. This inconsistent cash profile implies the company may repeatedly need external funding to support launches and manufacturing investments, raising execution risk over coming quarters.
Meiragtx Holdings News
MGTX FAQ
What was Meiragtx Holdings’s price range in the past 12 months?
Meiragtx Holdings lowest stock price was $6.62 and its highest was $13.94 in the past 12 months.
What is Meiragtx Holdings’s market cap?
Meiragtx Holdings’s market cap is $1.29B.
When is Meiragtx Holdings’s upcoming earnings report date?
Meiragtx Holdings’s upcoming earnings report date is Aug 06, 2026 which is in 34 days.
How were Meiragtx Holdings’s earnings last quarter?
Meiragtx Holdings released its earnings results on May 14, 2026. The company reported -$0.57 earnings per share for the quarter, beating the consensus estimate of -$0.606 by $0.036.
Is Meiragtx Holdings overvalued?
According to Wall Street analysts Meiragtx Holdings’s price is currently Undervalued.
Does Meiragtx Holdings pay dividends?
Meiragtx Holdings does not currently pay dividends.
What is Meiragtx Holdings’s EPS estimate?
Meiragtx Holdings’s EPS estimate is -0.31.
How many shares outstanding does Meiragtx Holdings have?
Meiragtx Holdings has 92,609,510 shares outstanding.
What happened to Meiragtx Holdings’s price movement after its last earnings report?
Meiragtx Holdings reported an EPS of -$0.57 in its last earnings report, beating expectations of -$0.606. Following the earnings report the stock price went down -0.201%.
Which hedge fund is a major shareholder of Meiragtx Holdings?
Currently, no hedge funds are holding shares in MGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Meiragtx Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.50 (171.74% Upside)
$27.50 (171.74% Upside)
Blogger Sentiment
Bullish
MGTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 144.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.53%
12-Months-Change
Fundamentals
Return on Equity
474.91%
Trailing 12-Months
Asset Growth
9.21%
Trailing 12-Months
Company Description
Meiragtx Holdings
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
MGTX Stock 12 Month Forecast
Average Price Target
$27.50
▲(171.74% Upside)
Technical Analysis
Ownership Overview
15.65% Insiders
1.86% Mutual Funds
57.31% Other Institutional Investors
19.98% Public Companies and
Individual Investors